FOXO3-induced oncogenic lncRNA CASC9 enhances gefitinib resistance of non-small-cell lung cancer through feedback loop
Authors:
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 287, 120012
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR MutationJournal of Thoracic Oncology, 2019
- Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5pDNA and Cell Biology, 2019
- Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysisLung Cancer, 2018
- RETRACTED ARTICLE: The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLCCell Cycle, 2018
- miR‐1‐3p and miR‐206 sensitizes HGF‐induced gefitinib‐resistant human lung cancer cells through inhibition of c‐Met signalling and EMTJournal of Cellular and Molecular Medicine, 2018
- Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysisInternational Journal of Cancer, 2017
- Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trialAnnals of Oncology, 2017
- Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLCLung Cancer, 2017
- Targeted Therapy and Immunotherapy for Lung CancerSurgical Oncology Clinics of North America, 2016
- Wnt Signaling Pathway in Non-Small Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2013